无症状女性子宫内膜癌风险预测(PRECISION):模型开发与外部验证
模型外部验证校准良好(校准斜率1.14,95%CI 1.11-1.17,E/O 1.03,95%CI 1.01-1.05),区分度中等/良好(C统计量0.70,95%CI 0.69-0.70),净获益优于既往模型。
要点
- PRECISION模型纳入年龄、BMI、腰围、月经初潮、绝经及末次分娩年龄、激素替代、他莫昔芬和口服避孕药使用、2型糖尿病、吸烟及肠癌家族史。
- 外部验证校准斜率1.14(95%CI 1.11-1.17),E/O 1.03(95%CI 1.01-1.05),C统计量0.70(95%CI 0.69-0.70)。
- 模型净获益优于既往开发的模型,可用于英国全科实践中的靶向资源分配。
核心结论
- PRECISION模型使用易测量的人体测量学、生殖、个人及家族史指标,能较准确地量化女性10年子宫内膜癌风险。
- 其用途可确定初级子宫内膜癌预防试验的入选资格,并用于英国全科实践中的靶向资源分配。
研究设计与样本
- 研究类型为队列研究;模型开发使用UK Biobank,外部验证使用链接的初级保健(CPRD)与二级保健(HES)、死亡(ONS)及癌症登记(NRCAS)数据集。
- 研究人群为45-60岁、无子宫内膜癌病史或子宫切除史的女性;模型开发纳入222031名女性(902例子宫内膜癌新发病例),外部验证纳入3094371名女性(8585例子宫内膜癌病例)。
- 模型开发使用灵活参数生存模型,采用逐步后退法以最小化赤池信息准则;外部验证通过灵活校准图、期望与观察比(E/O)、C统计量及决策曲线分析评估模型表现。
- 主要结局指标为索引日期后1-10年内子宫内膜癌诊断。
主要发现
- 最终模型纳入年龄、体重指数、腰围、月经初潮年龄、绝经年龄、末次分娩年龄、激素替代治疗、他莫昔芬使用、口服避孕药使用、2型糖尿病、吸烟及肠癌家族史。
- 外部验证校准良好:校准斜率1.14(95%CI 1.11-1.17),E/O 1.03(95%CI 1.01-1.05)。
- 外部验证区分度为中等/良好:C统计量0.70(95%CI 0.69-0.70)。
- 与既往开发的模型相比,PRECISION模型的净获益有所改善。
关键数值与推荐
- 模型开发样本222031名女性,其中子宫内膜癌新发病例902例;外部验证样本3094371名女性,其中子宫内膜癌病例8585例。
- 外部验证校准斜率1.14(95%CI 1.11-1.17),E/O 1.03(95%CI 1.01-1.05)。
- 外部验证C统计量0.70(95%CI 0.69-0.70)。
临床怎么用
- 作者认为,PRECISION模型可用于确定初级子宫内膜癌预防试验的入选资格,并用于英国全科实践中的靶向资源分配。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Develop an endometrial cancer risk prediction model and externally validate it for UK primary care use. DESIGN: Cohort study. SETTING: The UK Biobank was used for model development and a linked primary (Clinical Practice Research Datalink, CPRD) and secondary care (HES), mortality (ONS) and cancer register (NRCAS) dataset was used for external validation. POPULATION: Women aged 45-60 years with no history of endometrial cancer or hysterectomy. METHODS: Model development was performed using a flexible parametric survival model and stepwise backward selection aiming to minimise the Akaike information criterion. Model performance on external validation was assessed through flexible calibration plots, calculation of the expected to observed ratio and C-statistic and decision curve analysis. MAIN OUTCOME MEASURES: Endometrial cancer diagnosis within 1-10 years of the index date. RESULTS: Model development included 222 031 women (902 incident endometrial cancer cases) and external validation 3 094 371 women (8585 endometrial cancer cases). The final model (with equation provided) incorporated age, body mass index, waist circumference, age at menarche, menopause and last birth, hormone replacement, tamoxifen and oral contraceptive pill use, type 2 diabetes, smoking and family history of bowel cancer. It was well calibrated on external validation (calibration slope 1.14, 95% confidence interval [CI] 1.11-1.17, E/O 1.03, 95% CI 1.01-1.05), with moderate/good discrimination (C-statistic 0.70, 95% CI 0.69-0.70) and had improved net benefit compared with previously developed models. CONCLUSIONS: The Predicting risk of endometrial cancer in asymptomatic women model (PRECISION), using easily measurable anthropometric, reproductive, personal and family history, accurately quantifies a woman's 10-year risk of endometrial cancer. Its use could determine eligibility for primary endometrial cancer prevention trials and for targeted resource allocation in UK general practices.
引用
- Kitson SJ, Crosbie EJ, Evans DG, et al. Predicting risk of endometrial cancer in asymptomatic women (PRECISION): Model development and external validation. BJOG. 2023. PMID: 38073256. doi:10.1111/1471-0528.17729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。